



Dr. Jacob Pendergrast, Sickle Cell Disease

▶ PRINCIPLES

- ▶ Decr HgbS%, generally more important than increasing total Hgb
- ▶ Benefit only with high-shear vasculature
- ▶ Ceiling of Hgb ~100 g/L

▶ WEAK EVIDENCE WITH PREGNANCY

- ▶ Available evidence suggests more benefit for mom than developing fetus
- ▶ There may be exceptions (eg., signs of placental insufficiency, prev IUGR)

▶ CAUTION WITH SEVERE ANEMIA

- ▶ Aplastic crisis: *volume overload*
- ▶ Sequestration: *autotransfusion*
- ▶ Hyperhemolysis: *worsening anemia*

▶ GOOD EVIDENCE FOR STROKE PREVENTION

- ▶ Transfusion indicated for all children with high-risk dopplers and history of stroke
- ▶ Smaller value for children with SCIs
- ▶ Limited evidence in adults; look for other causes, caution with hemorrhagic stroke

▶ NUANCED APPROACH FOR SURGERY

- ▶ Usually not needed for low-risk patient with low risk procedure
- ▶ Indicated for everyone else, top-up vs exchange depends on comorbidity, procedure risk, baseline hemoglobin

▶ THERAPEUTIC TRANSFUSION IF ACUTE ORGAN COMPROMISE

- ▶ Limited evidence, but consensus supports transfusion for acute stroke, acute chest syndrome, sickle hepatopathy
- ▶ Other situations: "if all else fails"

▶ SELECTION OF RBCs MUST BE DONE WITH CARE!

- ▶ Tell your blood bank early that your patient has sickle cell, provide detailed transfusion history



Congenital Coag – VWD, Hemophilia, Dr. Michelle Sholzberg


- The bleeding history is the most important test of hemostasis

Von Willebrand Disease

- Diagnosis: 3 Clinical Components
 - Bleeding Symptoms
 - +/- Family History
 - Laboratory results

Bleeding Symptoms	Treatment
Mucocutaneous <ul style="list-style-type: none"> • Menorrhagia • Epistaxis • Bruising • Excessive bleeding from minor wounds • GI bleeding • Oral cavity/post-dental procedure • Post-operative • Post-partum Musculoskeletal (Type 3 VWD) <ul style="list-style-type: none"> • Hemarthrosis • Soft tissue, muscle hematomas 	<ul style="list-style-type: none"> • Call Hematology/Transfusion Medicine • DDAVP (Desmopressin) • Anti-fibrinolytic agents (TXA) • Transfusion based – VWF:FVIII concentrate <ul style="list-style-type: none"> – Humate-P or Wilate

Hemophilias:



Bleeding Symptoms	Treatment
<ul style="list-style-type: none"> - Musculoskeletal bleeding <ul style="list-style-type: none"> o Hemarthrosis o Intra-muscular hematoma - Mouth bleeding, epistaxis - Intracranial bleeding - Bleeding with trauma, procedures, surgery - Menorrhagia (symptomatic carriers) 	<ul style="list-style-type: none"> • Call Hematology/Transfusion Medicine • Anti-fibrinolytic agents (TXA) • Transfusion based – specific factor concentrate <ul style="list-style-type: none"> – Factor VIII: Xyntha, Kovaltry, Nuwiq, Adynovate – Factor IX: Benefix, Rebinyn • DDAVP/Desmopressin – for mild hemophilia A (FVIII >10%)

Resources

- "[Principles of Management of Urgent Bleeding in Hemophilia](#)" - developed by Dr. Jerry Teitel
- [Blood Easy: Coagulation Simplified](#) – developed by ORBCoN
- [Illustrated Review of Bleeding Assessment Tools and Coagulation tests](#) (Elbaz, Sholzberg)

TRANSFUSION CAMP RESOURCES ARE DEVELOPED BY TRANSFUSION CAMP FACULTY FOR EDUCATIONAL PURPOSES ONLY. THE RESOURCES **MUST NOT BE USED OR DISTRIBUTED OUTSIDE OF TRANSFUSION CAMP** WITHOUT THE CONSENT OF THE TRANSFUSION CAMP ORGANIZERS. THE MATERIALS ARE NOT INTENDED TO BE A SUBSTITUTE FOR THE ADVICE OF A PHYSICIAN AND SHOULD BE ASSESSED IN THE CONTEXT OF THE APPLICABLE MEDICAL, LEGAL AND ETHICAL REQUIREMENTS IN ANY INDIVIDUAL CASE. PROVIDE FEEDBACK ON TRANSFUSION CAMP RESOURCES OR ENQUIRE ABOUT TRANSFUSION CAMP BY CONTACTING TRANSFUSIONCAMP@BLOOD.CA.